EARS

6-K - Altamira Therapeutics Ltd. (0001601936) (Filer)

6-K - Auris Medical Holding Ltd. (0001601936) (Filer)

Bentrio™ formulation well tolerated in vitro on human nasal epitheliumUp to 99% reduction of SARS-CoV-2 viral titer with prophylactic treatment vs. controlsViral titer reduced 12- or 14-fold vs. controls when treatment started 24 or 30 h post infection Hamilton, Bermuda, July 14, 2021 – Auris Medical Holding Ltd. (NASDAQ:EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced additional preclinical data in a model of primary human nasal airway epithelium from its Bentrio™ (AM-301) nasal spray development program in SARS-CoV-2. AM-301 was found to be safe in vitro, and it sign

Treatment of KRAS-driven colorectal cancer selected as first therapeutic indication for OligoPhore™ platformCompany to launch development program under project code AM-401 with aim of IND submission in late 2022 Hamilton, Bermuda, July 6, 2021 – Auris Medical Holding Ltd. (NASDAQ:EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the selection of mutant KRAS-driven colorectal cancer as the first therapeutic indication for its OligoPhore™ oligonucleotide delivery platform. The Company intends to develop the treatment under project code AM-401 with submission of an IND tar

Hamilton, Bermuda, June 28, 2021 – Auris Medical Holding Ltd. (NASDAQ:EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced that its affiliate Altamira Medica Ltd. will start the market roll-out of Bentrio™, its nasal spray for protection against airborne viruses and allergens, by launching it in Germany. Bentrio™ will shortly become available through selected online pharmacies; over the coming months, market coverage will be expanded progressively through additional distribution channels and in further countries. "Following the intense and concerted efforts by our team and e

Treatment with OligoPhoreTM siRNA stops aggressive ATLL tumor growth to near zeroSignificant reduction in tumor size, spleen size and peripheral blood lymphocyte countsResults add to extensive body of evidence for effective OligoPhoreTM enabled delivery of nucleic acids to extrahepatic tissues Hamilton, Bermuda, June 21, 2021 – Auris Medical Holding Ltd. (NASDAQ:EARS), a company dedicated to addressing unmet medical needs through RNA therapeutics, allergy and viral infection protection, and inner ear therapeutics, today announced the publication of positive results from an in vivo study demonstrating significant inhibition of tumor growth by siRNA knock-down of NF-κB employing its OligoP

6-K - Auris Medical Holding Ltd. (0001601936) (Filer)

EFFECT - Auris Medical Holding Ltd. (0001601936) (Filer)

6-K - Auris Medical Holding Ltd. (0001601936) (Filer)

Entering field of RNA therapeutics through acquisition of Trasir Therapeutics, Inc.Trasir's innovative peptide-based OligoPhoreTM platform designed to enable extrahepatic delivery of oligonucleotidesTrasir's founder, Dr. Samuel Wickline, joining leadership team as Chief Scientific OfficerStrategic repositioning around RNA therapeutics and plans for spin-off or divestiture of existing programs in medium termExtraordinary general meeting of shareholders to vote on change of Company's name to Altamira Therapeutics Ltd. and election of Margrit Schwarz as new Board memberConference call and webcast today at 8 am EDT Hamilton, Bermuda, June 3, 2021 – Auris Medical Holding Ltd. (NASDAQ:EARS), a

POS AM - Auris Medical Holding Ltd. (0001601936) (Filer)

POS AM - Auris Medical Holding Ltd. (0001601936) (Filer)

Hamilton, Bermuda, June 1, 2021 – Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergology, today announced that its affiliate Altamira Medica Ltd. has started preparations for the conduct of a study with its BentrioTM nasal spray for protection against airborne viruses and allergens in India. The study will seek to evaluate the efficacy of BentrioTM in the prevention and treatment of acute Covid-19 and shall start recruitment in the third quarter 2021 subject to regulatory and ethics committee approval. "In our studies in human nasal epithelium cells, Bentrio

Hamilton, Bermuda, May 28, 2021 – Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that Chairman and CEO Thomas Meyer will present at the LD Micro Invitational XI investor conference on Wednesday June 9, 2021, at 11:00 a.m. EST (Track 2). The event will be webcast live and available via the event homepage https://ldmicrojune2021.mysequire.com. About Auris Medical Auris Medical is a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy a

Meeting essential requirements for marketing BentrioTM in Europe under CE markOn track for first product launch in Europe towards end of Q2 2021 Hamilton, Bermuda, May 25, 2021 – Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, and its affiliate Altamira Medica Ltd. today announced that it has successfully completed the conformity assessment procedure for marketing the BentrioTM nasal spray in the member states of the European Union (EU). The product, which is intended to help protect against airborne allergens and viruses, is considered

SC 13D/A - Auris Medical Holding Ltd. (0001601936) (Subject)

6-K - Auris Medical Holding Ltd. (0001601936) (Filer)

Hamilton, Bermuda, May 14, 2021 – Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today announced that it has reached the midpoint for enrollment in Part B of its Phase 2 proof-of-concept trial of AM-125 (intranasal betahistine) in the treatment of acute peripheral vertigo. In Part B of the TRAVERS trial, the Company will enroll 72 patients who suffer from acute peripheral vertigo following neurosurgery. They are randomized to receive either 10 or 20 mg of intranasal betahistine or a placebo three times daily for four weeks. The improv

BentrioTM meets primary efficacy endpoint in clinical evaluation in allergic rhinitisClinically relevant and significant reduction in nasal symptomsSuperior efficacy ratings by patients and clinicians   Pre-submission meeting with FDA supports 510(k) regulatory pathway Hamilton, Bermuda, May 7, 2021 – Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, and its affiliate Altamira Medica Ltd. today announced additional details on the outcomes from the clinical investigation of its BentrioTM nasal spray in allergic rhinitis and provided an upda

6-K - Auris Medical Holding Ltd. (0001601936) (Filer)

6-K - Auris Medical Holding Ltd. (0001601936) (Filer)

Clinical evaluation of AM-301 nasal spray in allergic rhinitis meets primary endpoint Extended protection achieved over several hoursPreliminary preclinical data suggest therapeutic utility post SARS-CoV-2 infectionProduct launch under BentrioTM brand in selected European countries towards end of Q2 2021  Hamilton, Bermuda, April 13, 2021 – Auris Medical Holding Ltd. (NASDAQ:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, and its affiliate Altamira Medica Ltd. today provided an update on its AM-301 program for protection against airborne viruses and allergens. "We are ve

Clinical evaluation of AM-301 nasal spray in allergen protection progressingLaunch of AM-301 expected in selected markets towards the end of second quarter 2021 Phase 2 trial with AM-125 in acute vertigo expected to complete enrollment in third quarter 2021Equity and cash position significantly strengthenedStrategy review ongoing  Hamilton, Bermuda, March 31, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology, rhinology and allergy and CNS disorders, today provided a business update and announced second half and full year 2020 financial results. “The 2020 business yea

6-K - Auris Medical Holding Ltd. (0001601936) (Filer)

20-F - Auris Medical Holding Ltd. (0001601936) (Filer)